2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Directors’ Report continued REMUNERATION REPORT (AUDITED) (CONTINUED) Performance Rights holdings of key management personnel (continued) All performance rights granted to key management personnel have been issued in accordance with the provisions of the Employee Conditional Rights Scheme (ECRS). No performance rights have lapsed during the year. No performance rights vested or were exercised during the year. No performance rights were issued prior to 1 January 2011. 1,150,000 performance rights were cancelled during the year. All performance rights expire on 30 June 2016. 50 PHOSPHAGENICS ANNUAL REPORT 2012
Directors’ Report continued REMUNERATION REPORT (AUDITED) (CONTINUED) Shareholdings of Key Management Personnel 2012 01 Jan 12 Balance No. Granted as remuneration No. Net other change No. 31 Dec 12 Balance No. Non Executive Directors Addison, J.L 22,473 - - 22,473 Clarke, D 35,484 - - 35,484 James, S - - - - Webb, S 111,000 - - 111,000 Executive Directors Rosen, H 64,226,436 - - 64,226,436 Ogru, E 5,711,610 - - 5,711,610 Key Management Personnel Alsop, H - - - - Gavin, P 99,000 - - 99,000 Arnott, A - - - - Butala, D - - - - El-Tamimy, M - - - - Rosen, J 2,000,068 - - 2,000,068 Kyriakou, K - - - - Moses, G - - - - Totals 72,206,071 - - 72,206,071 51 2011 01 Jan 11 Balance No. Granted as remuneration No. Net other change No. 31 Dec 11 Balance No. Non Executive Directors Addison, J.L 19,000 - 3,473 22,473 Clarke, D 30,000 - 5,484 35,484 James, S - - - - Webb, S 110,000 - 1,000 111,000 Executive Directors Rosen, H 64,226,436 - - 64,226,436 Ogru, E 5,711,610 - - 5,711,610 Key Management Personnel Banti, F - - - - Gavin, P 99,000 - - 99,000 Arnott, A - - - - Butala, D - - - - Harrison, K - - - - Kyriakou, K - - - - Libinaki, R 344,451 - - 344,451 Totals 70,540,497 - 9,957 70,550,454 DIRECTOR’S REPORT
Page 1 and 2: 20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4: highlights March... April... May...
Page 5 and 6: 03 Jonathan Addison Chairman & Inde
Page 7 and 8: COLLABORATIONS Strategic Collaborat
Page 9 and 10: The Phosphagenics Evolution THE STO
Page 11 and 12: “ We also reached agreement with
Page 13 and 14: Overview of our opioid development
Page 15 and 16: 13 is branded as Butrans or Norspan
Page 17 and 18: Personal Care ASHLAND INC (FORMERLY
Page 19 and 20: BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22: cellulite contour crème BioElixia
Page 23 and 24: Intellectual Property Title Countri
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 41 and 42: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47 and 48: Exercise Price Expiry Date Net othe
Page 49 and 50: Exercise Price Expiry Date Net othe
Page 51: Fair value per performance right at
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74: Application date of standard Impact
Page 103 and 104:
Notes to the consolidated fi nancia
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Independent Auditor’s Report 111
Page 115 and 116:
Additional Shareholder Information
Page 117 and 118:
Additional Shareholder Information
Page 119:
corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

Create successful ePaper yourself

Delete template?

Save as template?